Evonik Industries, OPX Biotechnologies sign development agreement
OPX Biotechnologies Inc. and Evonik Industries AG have announced an agreement to jointly develop certain biobased specialty chemicals. The joint-development agreement signed May 3 calls for OPXBIO to use its proprietary EDGE (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
“There’s a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively,” said Thomas Haas, vice president Science-to-Business Center Biotechnology of Creavis, the strategic research and development unit of Evonik.
“Evonik is a leading global specialty chemicals company, and we’re looking forward to helping them expand their portfolio of bio-based chemicals,” said Charles R. (Chas) Eggert, OPXBIO president and CEO. “The bio-process we’re developing has the potential to create economic and sustainable versions of products we use in our everyday lives.” According to the agreement, OPXBIO will also be able to market bio-based products resulting from the Evonik collaboration.